Answers are grounded in this paper and cite their sources.
Objective: To assess the effects of dupilumab on serum T-ALP levels (as a proxy for bone mineralization) and height among children aged 2 to <12 years with moderate-to-severe AD.
No takes yet. Share an insight, caveat, or question.
Irvine et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: